Compare Linde PLC (LIN) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs Travere Therapeutics Inc. Common Stock — how do they compare? Linde PLC trades at $495.3 (market cap $226.85B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Linde PLC is far larger — about 46.5× Travere Therapeutics Inc. Common Stock's market cap, and Linde PLC pays a 1.3% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Linde PLC for 89 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| LIN | TVTX | |
|---|---|---|
Market Cap | $226.85B | $4.88B |
Volume | 1,386,042 | 1,668,577 |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $67.52 |
52-Week Low | $389.38 | $26.79 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $249.97B | $5.01B |
Dividend Yield | 1.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $492.11, up 0.98% today, near its 52-week high. The stock shows a bullish technical trend with strong fundamentals, including a 20.43% net income margin and consistent earnings beats. Recent news highlights its role in AI chip supply chains, while analyst consensus remains strongly positive with a $558.91 price target.
Outlook is favorable given robust profitability and growth in electronics end-markets, but risks include elevated valuation multiples and rising debt levels. The stock offers upside potential aligned with Wall Street optimism, though investors should weigh margin pressures and capital expenditure trends.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
